ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2010, p. 924–926 Vol. 54, No. 2
Copyright © 2010, American Society for Microbiology. All Rights Reserved.
Pharmacokinetics of Ertapenem following Intravenous and
Subcutaneous Infusions in Patients
Denis Frasca,1,3 Sandrine Marchand,1,2,3 Franck Petitpas,1,3 Claire Dahyot-Fizelier,1,2,3
William Couet,1,2,3* and Olivier Mimoz1,2,3
INSERM, ERI-23, Poˆle Biologie Sante´, 40 Avenue du Recteur Pineau, Poitiers, France1; Universite´ de Poitiers,
UFR Me´decine-Pharmacie, 6 Rue de la Mile´trie, Poitiers, France2; and CHU Poitiers, 2 Rue de la Mile´trie,
Received 22 June 2009/Returned for modification 28 July 2009/Accepted 18 November 2009
Steady-state pharmacokinetics of ertapenem were compared in patients after 1-g intravenous and subcutaneous
(s.c.) infusions. Bioavailability was 99% 18% after s.c. administration, but peaks were reduced by
about 1⁄2 (43 29 versus 115 28g/ml) and times to peak were delayed. Simulations based on unbound
concentrations show that time over the MIC should always be longer than 30% to 40% of the dosing interval,
suggesting that s.c. infusion could be an alternative in patients with reduced vascular access.